For investor inquiries, please contact:
Eric Rojas, Vice President, Investor Relations
Doug Snow, Associate Director, Communications and Investor Relations
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company’s first compound, STK-001 is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. The company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the company’s belief in the broad potential for its proprietary approach.
September 22, 2021
September 21, 2021
August 10, 2021
Data Provided by Refinitiv. Minimum 15 minutes delayed.
September 28, 2021 at 4:00 PM EDT
September 21, 2021 at 8:30 AM EDT
August 12, 2021 at 12:30 PM EDT